Daratumumab Depletes CD38 + Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma

Jakub Krejcik, MD1,2 ; Tineke Casneuf, PhD3 ; Inger S. Nijhof, MD1 ; Bie Verbist, PhD3 ; Jaime Bald, BS4 ; Torben Plesner, MD2 ; Khaja Syed, MS4 ; Kevin Liu, PhD5 ; Niels W.C.J. van de Donk, MD1 ; Brendan M. Weiss, MD6 ; Tahamtan Ahmadi, MD4 ; Henk M. Lokhorst, MD1 ; Tuna Mutis, MD1 ; and A. Kate Sasser, PhD4 1Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands 2Vejle Hospital and University of Southern Denmark, Vejle, Denmark 3Janssen Research & Development, Beerse, Belgium 4Janssen Research & Development, LLC, Spring House, PA, USA 5Janssen Research & Development, LLC, Raritan, NJ, USA 6Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA